MPO-ANCA associated vasculitis | Controls (n = 40) | ||
---|---|---|---|
Active-vasculitis (n = 30) | Inactive-vasculitis (n = 30) | ||
Age (years) | 71.4 ± 14.2 | 69.7 ± 13.2 | 69.3 ± 12.0 |
Gender (male:female) | 17: 13 | 17: 13 | 21: 19 |
Birmingham vasculitis activity score | 20.7 ± 5.2*, ** | 0 ± 0 | |
Clinical symptoms | |||
Fever | 21 (70%)* | 0 (0%) | |
Weight loss | 10 (33%)* | 0 (0%) | |
Arthralgia | 22 (73%)* | 0 (0%) | |
Episcleritis or uvitis | 2 (7%) | 0 (0%) | |
Sinusitis | 1 (3%) | 0 (0%) | |
Hearing loss | 3 (10%) | 0 (0%) | |
Alveolar hemorrhage | 5 (17%) | 0 (0%) | |
Interstitial lung disease | 15 (50%) | 13 (43%) | |
Arrhythmia | 3 (10%) | 0 (0%) | |
Pericarditis | 2 (7%) | 0 (0%) | |
Heart failure | 9 (30%)* | 0 (0%) | |
Rapidly progressive glomerulonephritis | 25 (83%)* | 0 (0%) | |
Peripheral nerve damage | 1 (3%) | 0 (0%) | |
Laboratory data | |||
ANCA titer (U/mL) | 255.7 ± 178.8*, ** | 14.2 ± 30.4 | |
White blood cell (/mm3) | 9483 ± 3380*, ** | 8923 ± 3234** | 5763 ± 1482 |
Hemoglobin conc. (g/dL) | 9.1 ± 2.0*, ** | 11.7 ± 1.8 | 12.1 ± 2.0 |
Platelet count (104/mm3) | 27.2 ± 12.0*, ** | 21.2 ± 5.4 | 20.2 ± 6.0 |
Serum albumin (g/dL) | 3.05 ± 0.60*, ** | 3.74 ± 0.37** | 4.10 ± 0.34 |
Serum creatinine (mg/dL) | 4.55 ± 3.33*, ** | 3.26 ± 3.96 | 1.76 ± 1.48 |
Serum C-reactive protein (mg/dL) | 7.92 ± 6.87*, ** | 0.18 ± 0.16 | 0.09 ± 0.12 |
Serum 20S-proteasome (mg/dL) | 3414.6 ± 2738.9*, ** | 366.4 ± 128.4 | 234.9 ± 90.1 |
Doses of prednisolone (mg daily) | 0 ± 0* | 5.00 ± 1.97 |